SomnoMed Limited (ASX:SOM)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Production and Sale of Products Treating Sleep Disordered Breathing	111.49M	91.65M	83.62M	72.58M	62.71M
Production and Sale of Products Treating Sleep Disordered Breathing Growth	21.65%	9.61%	15.20%	15.75%	9.44%
Total	111.49M	91.65M	83.62M	72.58M	62.71M
Total Growth	21.65%	9.61%	15.20%	15.75%	9.44%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
North America (Excl. North America (RSS Component))	43.23M	32.94M	30.33M	24.83M	18.56M
North America (Excl. North America (RSS Component)) Growth	31.23%	8.62%	22.15%	33.74%	-9.19%
Europe	62.70M	54.17M	48.89M	43.52M	40.09M
Europe Growth	15.75%	10.79%	12.35%	8.55%	21.02%
Asia Pacific	26.23M	21.74M	18.16M	15.45M	13.33M
Asia Pacific Growth	20.66%	19.69%	17.56%	15.88%	13.84%
Intersegment Eliminations	-20.67M	-17.21M	-13.77M	-11.22M	-9.28M
Total	111.49M	91.65M	83.62M	72.58M	62.71M
Total Growth	21.65%	9.61%	15.20%	15.75%	9.44%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 27, 2026

Data Sources Report a data error